Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suguru Shirotake

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Hinyokika Kiyo. Acta Urologica Japonica|December 29, 2010
[Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma]Takahiko Yoshii, Akio Horiguchi, Suguru Shirotake, et al.
The Prostate|September 18, 2009
Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancerTakeo Kosaka, Akira Miyajima, Suguru Shirotake, et al.
Annals of Surgical Oncology|August 9, 2012
Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancerKazuyuki Yuge, Akira Miyajima, Nobuyuki Tanaka, et al.
Cureus|December 23, 2024
Initial Experience With Senhance-Assisted Laparoscopic Partial Cystectomy Using the Double Bipolar Method With 3 mm Bipolar InstrumentsJunya Kawabata, Go Kaneko, Suguru Shirotake, et al.
Molecular and Clinical Oncology|June 8, 2017
Determining the optimum way to maintain quality of life for very elderly patients with advanced bladder cancer and poor performance status: A case reportKenjiro Suzuki, Fuminari Hanashima, Suguru Shirotake, et al.
Plos One|October 20, 2022
Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy aloneKent Kanao, Takayuki Takahashi, Yuta Umezawa, et al.
Annals of Nuclear Medicine|January 5, 2021
Test-retest repeatability of quantitative bone SPECT/CTTomohiko Yamane, Kenji Fukushima, Suguru Shirotake, et al.
Molecular and Clinical Oncology|April 23, 2019
Meningeal carcinomatosis from bladder cancer: A case report and review of the literatureYuta Umezawa, Suguru Shirotake, Go Kaneko, et al.
Japanese Journal of Clinical Oncology|November 27, 2018
Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective studySuguru Shirotake, Soichi Makino, Kenjiro Suzuki, et al.
Anticancer Research|August 2, 2019
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell CarcinomaSuguru Shirotake, Kimiharu Takamatsu, Ryuichi Mizuno, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Hinyokika Kiyo. Acta Urologica Japonica|December 29, 2010
[Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma]Takahiko Yoshii, Akio Horiguchi, Suguru Shirotake, et al.
The Prostate|September 18, 2009
Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancerTakeo Kosaka, Akira Miyajima, Suguru Shirotake, et al.
Annals of Surgical Oncology|August 9, 2012
Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancerKazuyuki Yuge, Akira Miyajima, Nobuyuki Tanaka, et al.
Cureus|December 23, 2024
Initial Experience With Senhance-Assisted Laparoscopic Partial Cystectomy Using the Double Bipolar Method With 3 mm Bipolar InstrumentsJunya Kawabata, Go Kaneko, Suguru Shirotake, et al.
Molecular and Clinical Oncology|June 8, 2017
Determining the optimum way to maintain quality of life for very elderly patients with advanced bladder cancer and poor performance status: A case reportKenjiro Suzuki, Fuminari Hanashima, Suguru Shirotake, et al.
Plos One|October 20, 2022
Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy aloneKent Kanao, Takayuki Takahashi, Yuta Umezawa, et al.
Annals of Nuclear Medicine|January 5, 2021
Test-retest repeatability of quantitative bone SPECT/CTTomohiko Yamane, Kenji Fukushima, Suguru Shirotake, et al.
Molecular and Clinical Oncology|April 23, 2019
Meningeal carcinomatosis from bladder cancer: A case report and review of the literatureYuta Umezawa, Suguru Shirotake, Go Kaneko, et al.
Japanese Journal of Clinical Oncology|November 27, 2018
Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective studySuguru Shirotake, Soichi Makino, Kenjiro Suzuki, et al.
Anticancer Research|August 2, 2019
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell CarcinomaSuguru Shirotake, Kimiharu Takamatsu, Ryuichi Mizuno, et al.
Pageof 9